Zepbound tops Wegovy for weight loss in first head-to-head study comparing the drugs

A recent study published in the New England Journal of Medicine has revealed that individuals who take tirzepatide, sold under the brand names Zepbound and Mounjaro, may experience greater weight loss compared to those taking semaglutide, known as Ozempic and Wegovy. Over a 72-week period, tirzepatide users lost approximately 20% of their body weight, while semaglutide users lost around 14%.

Dr. Céline Gounder, a medical contributor for CBS News, highlighted the difference in weight loss between the two drugs, stating that on average, there was an eight-pound disparity. It is important to note that the study was funded by Lilly, the manufacturer of tirzepatide, which raises some concerns about bias. However, Gounder mentioned that the research appears legitimate and is supported by findings from other studies.

In response to the study, Novo Nordisk, the maker of Wegovy and Ozempic, emphasized that both drugs have shown significant weight reduction in clinical trials. They also highlighted the additional health benefits of these medications, such as improvements in blood pressure, diabetes management, and cholesterol levels.

Despite the positive outcomes associated with these drugs, the cost remains a barrier for many individuals. With an average out-of-pocket cost of over $1,000, affordability is a significant concern. While ordering directly from the drug manufacturers may reduce costs to under $500, only one in four insurance companies currently cover these medications for obesity. Gounder emphasized the need for expanded insurance coverage for these drugs, noting that there have been proposals to include them under Medicare.

Overall, the study underscores the potential benefits of tirzepatide and semaglutide in promoting weight loss and improving overall health outcomes. However, addressing the high cost and limited insurance coverage for these medications is crucial to ensure accessibility for individuals seeking effective obesity treatments.

Sara Moniuszko, a health and lifestyle reporter at CBSNews.com, provided valuable insights into the study findings and the broader implications for individuals struggling with obesity. Her expertise in health reporting adds depth to the discussion surrounding these innovative weight loss medications.